Medicine and Dentistry
Carbapenem
100%
Carbapenemase
64%
Klebsiella pneumoniae
55%
Intensive Care Medicine
42%
Bacteremia
38%
Central Venous Catheter
33%
Infection
33%
Avibactam Plus Ceftazidime
29%
Intensive Care Unit
27%
Antibiotics
26%
Diarrhea
25%
Antibiotic Therapy
25%
Mycobacteriosis
25%
Health Care Cost
25%
Intensive Care
25%
COVID-19
25%
Cohort Analysis
25%
Pseudomonas aeruginosa
25%
Vascular Access
25%
Venous Thromboembolism
25%
Polymerase Chain Reaction
25%
Outpatient Care
25%
Carbapenem-Resistant Enterobacteriaceae
25%
Program Director
25%
Prospective Cohort Study
25%
Diagnosis
25%
Bloodstream Infection
25%
Catheter Infection
25%
Cohort Effect
25%
Flu Like Syndrome
25%
Pathogen
25%
Inferior Vena Cava Filter
25%
Mixed Infection
25%
Polymerase Chain Reaction
18%
Odds Ratio
16%
Blood Culture
12%
Penicillinase
12%
Pseudomonas Infection
11%
Genetic Marker
10%
Klebsiella Pneumoniae Infection
10%
Monotherapy
8%
Cloaca
8%
Polymyxin
8%
Mortality Rate
8%
Charlson Comorbidity Index
7%
Prevalence
7%
Whole Genome Sequencing
6%
Broad-Spectrum Antibiotic
6%
Consultation
6%
Patient Care
5%
Keyphrases
Carbapenem-resistant Enterobacterales
50%
Ceftazidime-avibactam
29%
Klebsiella Pneumoniae Carbapenemase
25%
Mycobacterium Infections
25%
Medical Tourists
25%
Bloodstream Infection
25%
Clinical Outcomes
25%
Medicine Services
25%
Rapid Molecular Diagnostics
25%
Molecular Epidemiological Analysis
25%
Critical Care Unit
25%
Carbapenem-resistant Enterobacteriaceae
25%
Inferior Vena Cava Filter
25%
Newly Diagnosed
25%
Fungal Co-infections
25%
Gastrointestinal Panel
25%
Syndromic Diarrhea
25%
Klebsiella Pneumoniae Complex
25%
Bacterial Characteristics
25%
Infectious Diseases
25%
Access Model
25%
Venous Thromboembolism
25%
Bacteremia
25%
Intensive Care Unit
25%
Critical Care Medicine
25%
Community Exposure
20%
KPC-2
16%
Antibiotic Use
15%
PCR Test
12%
Time to Culture Positivity
12%
Utilization Outcomes
10%
Infectious Diseases Consultation
10%
Broad-spectrum Antibiotics
10%
Inferior Vena Cava Filter Retrieval
9%
Positive Blood Culture
8%
Monotherapy
8%
30-day Mortality
8%
KPC-3
8%
Appropriate Therapy
8%
Polymyxin
8%
Carbapenemase
6%
Carbapenemases
6%
Capsular Type
6%
Enterobacteriaceae Bacteraemia
6%
Pseudomonas Aeruginosa Isolates
5%
In-hospital Mortality
5%
Antibiotics
5%
Intensive Care Unit Team
5%
Critically Ill Patients
5%
Broad-spectrum Agents
5%
Pharmacology, Toxicology and Pharmaceutical Science
Carbapenem
100%
Klebsiella pneumoniae
75%
Carbapenemase
50%
Bacteremia
38%
Infection
36%
Avibactam Plus Ceftazidime
29%
Carbapenem Resistant Enterobacteriaceae
28%
SARS Coronavirus
25%
Prospective Cohort Study
25%
Pseudomonas aeruginosa
25%
Cohort Study
25%
Bloodstream Infection
25%
Mixed Infection
25%
Penicillinase
12%
Pseudomonas Infection
11%
Klebsiella Pneumoniae Infection
10%
Antibiotic Agent
8%
Mortality Rate
8%
Polymyxin
8%
Monotherapy
8%
Carbapenem Resistance
7%
Comorbidity
7%
All Cause Mortality
5%